CryoPort (NASDAQ:CYRX) Posts Earnings Results, Misses Expectations By $0.08 EPS

CryoPort (NASDAQ:CYRX) issued its earnings results on Tuesday. The company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.08), FiscalAI reports. The business had revenue of $45.45 million for the quarter, compared to the consensus estimate of $42.92 million. CryoPort had a negative return on equity of 11.07% and a net margin of 35.57%.

Here are the key takeaways from CryoPort’s conference call:

• Full-year revenue from continuing operations was $176.2M, above the prior guidance range, with Q4 double-digit growth; management guided 2026 revenue of $190M–$194M and expects positive adjusted EBITDA in H2 2026.
• Commercial cell & gene therapy momentum accelerated—commercial revenue rose 29% and now represents ~20% of revenue, while Cryoport supports a record 760 clinical trials and 20 commercial therapies, with 86 phase‑3 and 361 phase‑2 trials described as a “spring‑loaded” pipeline for future commercial revenue.
• Operational discipline and product innovation showed progress: gross margin improved to 47% with a $12M YoY adjusted EBITDA improvement, plus investments in global supply‑chain centers and new MVE product offerings (Fusion 800, CryoVerse, integrated monitoring) and enterprise AI adoption.
• The sale of CRYOPDP to DHL delivered a meaningful capital infusion and a strategic partnership expected to expand APAC/EMEA reach, but management noted integration and full benefit realization will take time.
• Guidance and upside remain sensitive to regulatory approvals, macro volatility and timing of commercial therapy ramps; product (MVE) sales are lumpy and management modeled only mid‑single‑digit product growth, leaving downside risk if approvals or commercial rollouts slow.

CryoPort Stock Performance

Shares of CryoPort stock opened at $8.49 on Wednesday. CryoPort has a 12 month low of $4.58 and a 12 month high of $11.45. The company has a quick ratio of 15.01, a current ratio of 15.77 and a debt-to-equity ratio of 0.40. The stock has a market cap of $425.09 million, a PE ratio of 7.26 and a beta of 1.69. The business has a fifty day simple moving average of $9.51 and a 200-day simple moving average of $9.41.

Insider Transactions at CryoPort

In other CryoPort news, Director Ramkumar Mandalam sold 11,570 shares of the firm’s stock in a transaction dated Wednesday, December 10th. The stock was sold at an average price of $9.99, for a total transaction of $115,584.30. Following the completion of the sale, the director directly owned 80,758 shares in the company, valued at approximately $806,772.42. This trade represents a 12.53% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Corporate insiders own 10.10% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. AQR Capital Management LLC boosted its position in CryoPort by 285.5% during the first quarter. AQR Capital Management LLC now owns 262,596 shares of the company’s stock valued at $1,597,000 after purchasing an additional 194,482 shares during the last quarter. Creative Planning acquired a new stake in shares of CryoPort during the 2nd quarter valued at about $96,000. Rhumbline Advisers lifted its holdings in shares of CryoPort by 17.6% during the 2nd quarter. Rhumbline Advisers now owns 92,098 shares of the company’s stock valued at $687,000 after buying an additional 13,778 shares during the last quarter. American Century Companies Inc. grew its stake in shares of CryoPort by 24.4% in the 2nd quarter. American Century Companies Inc. now owns 88,876 shares of the company’s stock valued at $663,000 after buying an additional 17,459 shares in the last quarter. Finally, Prudential Financial Inc. acquired a new position in CryoPort in the second quarter worth approximately $254,000. Institutional investors and hedge funds own 92.90% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the company. UBS Group increased their price objective on CryoPort from $11.00 to $12.50 and gave the company a “buy” rating in a research report on Wednesday, November 5th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of CryoPort in a research report on Monday, December 29th. Finally, Needham & Company LLC increased their price target on CryoPort from $12.00 to $13.00 and gave the company a “buy” rating in a research report on Wednesday. Eight analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $12.94.

About CryoPort

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.